China's National Centre for Biotechnology development claimed that the drug Favipiravir, developed almost 25 years back, showed 'favourable' results in treating Covid-19 in a clinical trial of 340 patients. Favipiravir is a drug molecule that was developed by Japanese drug maker Fujifilm and patented in 1995. The company plans to select the top two antibodies for a cocktail treatment targeting the SARSCoV-2 spike protein.